Please ensure Javascript is enabled for purposes of website accessibility

Why Achillion Pharmaceuticals Crashed Today

By Keith Speights - Dec 17, 2018 at 4:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Worries about an imminent clinical update sent the stock lower.

What happened

Shares of Achillion Pharmaceuticals (ACHN) had plunged 22.8% as of the market close on Monday. The sell-off appeared to reflect investor nervousness ahead of the biotech's announcement of interim clinical-trial data from phase 2 clinical trials in C3 glomerulopathy (C3G) and paroxysmal nocturnal hemoglobinuria (PNH) and phase 1 data for Achillion's next-generation factor D inhibitors.

So what

Today's drop might mean nothing for Achillion. It could just be another wild day for a highly volatile clinical-stage biotech stock.

Businessman looking at chart going down

Image source: Getty Images.

Achillion has experienced a crazy year so far in 2018. Its stock has swung up and down -- sometimes on related news and sometimes on no news at all. Investors have their hopes pinned on success for experimental factor D inhibitor ACH-4471.

However, it's possible that news of the phase 2 data for ACH-4471 leaked ahead of Achillion's update. If so, the big sell-off could mean that the interim results for the drug in treating C3G and/or PNH are disappointing. At the time of this writing, though, there was no way to know for sure if such a leak occurred. 

Now what

There's a lot riding on the performance of ACH-4471 in the phase 2 studies. The drug is Achillion's lead candidate. The biotech's other two pipeline programs are only in early stage clinical testing.

Tuesday could be a completely different story for Achillion if today's decline only stemmed from fear and worry rather than disappointing results. However, everything hinges on those results, which were scheduled to be announced at 4:30 p.m. EST today. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.